Perceptive Advisors BBIO Position
Exited9-Fund ConvergencePerceptive Advisors exited their position in BridgeBio Pharma Inc. (BBIO) in Q3 2024, after holding the stock for 7 quarters.
The position was first reported in Q1 2023 and has been tracked across 7 quarterly 13F filings.
BBIO is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 20.2% of float with 7.8 days to cover, indicating significant bearish positioning against the stock.
About BridgeBio Pharma Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Full company profile →Short Interest
20.2%
7.8 days to cover
Perceptive Advisors BBIO Position History
Frequently Asked Questions
Does Perceptive Advisors own BBIO?
No. Perceptive Advisors exited their position in BridgeBio Pharma Inc. (BBIO) in Q3 2024. They previously held the stock for 7 quarters.
How many hedge funds own BBIO?
9 specialist biotech hedge funds currently hold BBIO, including Cormorant Asset Management, Driehaus Capital, Deep Track Capital and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy BBIO?
Perceptive Advisors's position in BBIO was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's BBIO position increasing or decreasing?
Perceptive Advisors completely exited their BBIO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BBIOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →